↓ Skip to main content

Dove Medical Press

Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice

Overview of attention for article published in International Journal of Nanomedicine, July 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
4 X users
facebook
1 Facebook page

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
73 Mendeley
Title
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice
Published in
International Journal of Nanomedicine, July 2016
DOI 10.2147/ijn.s106736
Pubmed ID
Authors

Arvind Thakkar, Sushma Chenreddy, Astrid Thio, Wael Khamas, Jeffrey Wang, Sunil Prabhu

Abstract

Our previous studies have established the efficacy of chemopreventive regimens of aspirin and curcumin (CUR) encapsulated within solid lipid nanoparticles (SLNs) in combination with free sulforaphane (ACS combination) to prevent or delay the initiation and progression of pancreatic cancer, classified as one of the deadliest diseases with very low chances of survival upon diagnosis. Although toxicity of individual drugs and SLN has been studied previously, there are no studies in current literature that evaluate the potential toxicity of a combined regimen of ACS, especially when encapsulated within chitosan-SLNs (c-SLNs). Hence, objective of the current study was to investigate the potential toxic effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), subacute (28 days), and subchronic (90 days) administrations by oral gavage in BALB/c mice. Mice were administered the following regimens: saline, blank c-SLN, low-dose ACS c-SLN (2+4.5+0.16 mg/kg), medium-dose ACS c-SLN (20+45+1.6 mg/kg), and high-dose ACS c-SLN (60+135+4.8 mg/kg). The potential toxicity was evaluated based on animal survival, body weight, hematology, blood chemistry, and organ histopathology. During 3-day, 28-day, and 90-day study periods, no animal deaths were observed. Treatment with ACS c-SLNs did not cause alteration in complete blood counts and blood chemistry data. Histopathological examination of various organ sections (pancreas, heart, liver, kidney, and brain) appeared normal. Based on the results of this study, no signs of toxicity in acute, subacute, and subchronic studies following oral administration of ACS c-SLNs were found indicating that the oral dosing regimens were safe at the levels tested for long-term administration to prevent the onset of pancreatic cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 73 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 21%
Student > Ph. D. Student 8 11%
Student > Bachelor 8 11%
Researcher 4 5%
Student > Postgraduate 4 5%
Other 11 15%
Unknown 23 32%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 15 21%
Engineering 7 10%
Agricultural and Biological Sciences 7 10%
Biochemistry, Genetics and Molecular Biology 5 7%
Chemistry 4 5%
Other 11 15%
Unknown 24 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2016.
All research outputs
#14,600,874
of 25,374,917 outputs
Outputs from International Journal of Nanomedicine
#1,525
of 4,122 outputs
Outputs of similar age
#191,615
of 367,263 outputs
Outputs of similar age from International Journal of Nanomedicine
#40
of 121 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,122 research outputs from this source. They receive a mean Attention Score of 4.7. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,263 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.